Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis
This study has been completed.
Study NCT00002070   Information provided by NIH AIDS Clinical Trials Information Service
First Received: November 2, 1999   Last Updated: June 23, 2005   History of Changes

November 2, 1999
June 23, 2005
 
 
 
 
Complete list of historical versions of study NCT00002070 on ClinicalTrials.gov Archive Site
 
 
 
Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis
Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis

To determine whether co-administration of sargramostim (granulocyte-macrophage colony-stimulating factor; GM-CSF) improves tolerance to ganciclovir in patients previously intolerant because of neutropenia defined as an absolute neutrophil count less than 500 cells/mm3. To assess if improved tolerance of ganciclovir is associated with a favorable outcome as defined by a delayed time to progression of retinitis; to confirm the safety and co-administration of ganciclovir and GM-CSF; to assess the changes in the expression of HIV p24 antigen in the serum and number of T4+ lymphocytes in the blood of patients receiving ganciclovir with or without GM-CSF.

 
Phase III
Interventional
Treatment
  • Cytomegalovirus Retinitis
  • HIV Infections
  • Drug: Sargramostim
  • Drug: Ganciclovir
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
 
 
 

Inclusion Criteria

Patient must have the following:

  • AIDS as defined by CDC criteria.
  • Retinitis as diagnosed by the study ophthalmologist.
  • Performance status 0, 1, or 2.
  • Ability to give informed consent and suitability of intravenous access for scheduled blood tests.
  • Patient may have Kaposi's sarcoma or basal skin cancer.

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

  • Active acute infection requiring treatment.
  • Corneal, lens, or vitreal opacification which precludes examination of the fundi, or evidence of retinopathy.
  • Malignancy other than Kaposi's sarcoma (KS) or basal skin cancer.

Patients with the following are excluded:

  • Active acute infection requiring treatment.
  • Corneal, lens, or vitreal opacification which precludes examination of the fundi, or evidence of retinopathy.
  • Malignancy other than Kaposi's sarcoma (KS) or basal skin cancer.

Prior Medication:

Excluded:

  • Granulocyte macrophage colony-stimulating factor (GM-CSF).
  • Colony stimulating factor.
  • Interleukin 3.
  • Excluded within 7 days of study entry:
  • Zidovudine (AZT).
  • Trimethoprim / sulfamethoxazole (TMP / SMX).
  • Pyrimethamine.
  • Excluded within 30 days of study entry:
  • Biologic response modifiers.
  • Cytotoxic agents.
  • Investigational agents.

Prior Treatment:

Excluded:

  • Radiation therapy.

Required within 1 week of study entry:

  • One or more doses of ganciclovir.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00002070
 
005A, C88-059
Schering-Plough
 
 
NIH AIDS Clinical Trials Information Service
May 1991

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP